Clinical Trial Update: Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of NYX-783 in adults with Post-Traumatic Stress Disorder has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• NYX-783

Snippet

Sponsor: Aptinyx | Conditions: Post-Traumatic Stress Disorder | Phase 2 | Status: COMPLETED | Results posted: 2022-05-13